Detalles de la búsqueda
1.
In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022).
Antimicrob Agents Chemother
; 68(2): e0113223, 2024 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38205999
2.
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
Antimicrob Agents Chemother
; 68(5): e0158423, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526046
3.
Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021).
Eur J Clin Microbiol Infect Dis
; 42(4): 453-459, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36810724
4.
Evaluation of XGEN Multi Sepsis Flow Chip Molecular Assay for Early Diagnosis of Bloodstream Infection.
Curr Microbiol
; 80(7): 231, 2023 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37261596
5.
Susceptibility patterns of amphotericin B, itraconazole, posaconazole, voriconazole and caspofungin for isolates causing invasive mould infections from the SENTRY Antifungal Surveillance Program (2018-2021) and application of single-site epidemiological cutoff values to evaluate amphotericin B activity.
Mycoses
; 66(10): 854-868, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37431241
6.
Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
Antimicrob Agents Chemother
; 66(2): e0166721, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34807761
7.
Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
J Clin Microbiol
; 60(4): e0244921, 2022 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35249367
8.
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a ß-lactam/ß-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
J Antimicrob Chemother
; 77(10): 2642-2649, 2022 09 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35897129
9.
Comparative activity of newer ß-lactam/ß-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020.
Eur J Clin Microbiol Infect Dis
; 41(2): 319-324, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34657213
10.
Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020).
Eur J Clin Microbiol Infect Dis
; 41(5): 867-873, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35355158
11.
Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020).
Eur J Clin Microbiol Infect Dis
; 41(3): 477-487, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35041100
12.
Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections.
Med Mycol
; 60(5)2022 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35511210
13.
Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.
Mycoses
; 65(11): 1040-1044, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35778886
14.
Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
J Antimicrob Chemother
; 76(3): 659-666, 2021 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33276387
15.
In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe.
Antimicrob Agents Chemother
; 64(11)2020 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32778552
16.
Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe.
Antimicrob Agents Chemother
; 64(5)2020 04 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32094135
17.
Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018.
Antimicrob Agents Chemother
; 64(3)2020 02 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31907187
18.
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.
Antimicrob Agents Chemother
; 64(11)2020 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32900683
19.
Assessment of Tedizolid In Vitro Activity and Resistance Mechanisms against a Collection of Enterococcus spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018.
Antimicrob Agents Chemother
; 64(4)2020 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32015026
20.
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
J Antimicrob Chemother
; 75(10): 2907-2913, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32653914